An Wen-Ting, Hao Yu-Xia, Li Hong-Xia, Wu Xing-Kang
Department of Pharmacy, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
Department of Gastroenterology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China.
World J Clin Cases. 2024 Feb 16;12(5):951-965. doi: 10.12998/wjcc.v12.i5.951.
(H. pylori) infection is a major risk factor for chronic gastritis, affecting approximately half of the global population. H. pylori eradication is a popular treatment method for H. pylori-positive chronic gastritis, but its mechanism remains unclear. Urinary metabolomics has been used to elucidate the mechanisms of gastric disease treatment. However, no clinical study has been conducted on urinary metabolomics of chronic gastritis.
To elucidate the urinary metabolic profiles during H. pylori eradication in patients with chronic gastritis.
We applied LC-MS-based metabolomics and network pharmacology to investigate the relationships between urinary metabolites and H. pylori-positive chronic gastritis a clinical follow-up study.
Our study revealed the different urinary metabolic profiles of H. pylori-positive chronic gastritis before and after H. pylori eradication. The metabolites regulated by H. pylori eradication therapy include cis-aconitic acid, isocitric acid, citric acid, L-tyrosine, L-phenylalanine, L-tryptophan, and hippuric acid, which were involved in four metabolic pathways: (1) Phenylalanine metabolism; (2) phenylalanine, tyrosine, and tryptophan biosynthesis; (3) citrate cycle; and (4) glyoxylate and dicarboxylate metabolism. Integrated metabolomics and network pharmacology revealed that MPO, COMT, TPO, TH, EPX, CMA1, DDC, TPH1, and LPO were the key proteins involved in the biological progress of H. pylori eradication in chronic gastritis.
Our research provides a new perspective for exploring the significance of urinary metabolites in evaluating the treatment and prognosis of H. pylori-positive chronic gastritis patients.
幽门螺杆菌（H. pylori）感染是慢性胃炎的主要危险因素，影响着全球约一半的人口。根除幽门螺杆菌是治疗幽门螺杆菌阳性慢性胃炎的常用方法，但其机制尚不清楚。尿液代谢组学已被用于阐明胃病治疗的机制。然而，尚未有关于慢性胃炎尿液代谢组学的临床研究。
阐明慢性胃炎患者根除幽门螺杆菌期间的尿液代谢谱。
我们应用基于液相色谱-质谱联用的代谢组学和网络药理学来研究尿液代谢物与幽门螺杆菌阳性慢性胃炎之间的关系——一项临床随访研究。
我们的研究揭示了幽门螺杆菌阳性慢性胃炎患者根除幽门螺杆菌前后不同的尿液代谢谱。根除幽门螺杆菌治疗所调节的代谢物包括顺乌头酸、异柠檬酸、柠檬酸、L-酪氨酸、L-苯丙氨酸、L-色氨酸和马尿酸，它们参与了四条代谢途径：（1）苯丙氨酸代谢；（2）苯丙氨酸、酪氨酸和色氨酸生物合成；（3）柠檬酸循环；（4）乙醛酸和二羧酸代谢。综合代谢组学和网络药理学表明，髓过氧化物酶（MPO）、儿茶酚-O-甲基转移酶（COMT）、甲状腺过氧化物酶（TPO）、酪氨酸羟化酶（TH）、嗜酸性粒细胞过氧化物酶（EPX）、羧肽酶A1（CMA1）、多巴脱羧酶（DDC）、色氨酸羟化酶1（TPH1）和脂氧合酶（LPO）是慢性胃炎中根除幽门螺杆菌生物学过程的关键蛋白。
我们的研究为探索尿液代谢物在评估幽门螺杆菌阳性慢性胃炎患者治疗和预后中的意义提供了新的视角。
